Zymeworks surges on positive Phase 3 Ziihera data in HER2-positive cancer. Discover key catalysts and what’s next for ZYME ...

Shift verification effort from a single, time-consuming flat run to a more efficient, distributed, and scalable process.

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced it will be presenting new data ...

ACADIA 2025 brought together leading voices in tech and design to share how algorithms, software and data analysis will ...

Nuvalent (NUVL) has scheduled a webcast to present pivotal data from its Phase 1/2 ALKOVE-1 study. The presentation will focus on an investigational ALK-selective inhibitor for advanced non-small cell ...

Get the latest on Tectonic Therapeutic, Inc.'s clinical progress in pulmonary hypertension and market potential. Click for ...

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s ...

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in ...

Why you don’t want to miss this: Besides being the current leader in the metal AM market, EOS has been innovating at a rapid ...

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory ...

An announcement from Ashoka Whiteoak Emerging Markets Trust Plc ( ($GB:AWEM) ) is now available. Ashoka WhiteOak Emerging Markets Trust Plc ...